Australia's most trusted
source of pharma news
Sunday, 23 February 2025
Posted 21 February 2025 PM
ASX-listed Mayne Pharma announced a deal today to be acquired for $672 million by US pharma Cosette.
Cosette has agreed to pay $7.40 per share in cash, a 36.78 per cent premium over yesterday's closing price, and a 42 per cent premium to the 30-day volume weighted average price. However, it's a far cry from the roughly $2 billion market cap that represented the stock's peak in 2016.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.